CSI Market
Sign In | Register

Inhibikase Therapeutics Inc (IKT) Annual Balance Sheets

Annual · GAAP · USD millions
Access IKT quarterly Balance Sheets →
Balance sheet patterns shown here provide context for understanding Inhibikase Therapeutics Inc's financial stability and long-term positioning.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IKT/balance-sheets
https://api.csimarket.com/api/v1/companies/IKT/fundamentals
https://api.csimarket.com/api/v1/companies/IKT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Balance Sheet API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent139.22
Marketable Securities, Current SH39.54
Cash & Short-term Investments178.00
Accounts receivable0.00
Other Current Assets0.00
Prepaid Expense, Current AS1.00
Total Current Assets180.11
Equipment/Property/Plant Net0.00
Prepaid Expense, Noncurrent, Total PR1.00
Other Assets, Noncurrent0.00
Operating Lease Right Of Use Asset0.10
Total Assets181.20
Liabilities
Accounts Payable, Current AC1.16
Accrued Liabilities, Current AC4.08
Long-term Debt and Capital Lease Obligations, Current DE0.00
Other Liabilities, Current0.00
Total Current Liabilities8.30
Capital Lease Obligations, Noncurrent LO0.00
Total Long-term Debt0.00
Contingent Consideration Liability-
Total Liabilities8.30
Stockholders' Equity
Common Stock Value0.13
Additional Paid In Capital Common Stock315.43
Retained Earnings / Accumulated Deficit-142.68
Accumulated Other Comprehensive Income0.02
Other Equity0.02
Common Stockholder's Equity172.90
Total Stockholder's Equity172.90
Liabilities & Stockholder's Equity181.20
4 historic quarters locked

Sign in to unlock the full Inhibikase Therapeutics Inc balance sheet history.

Sign In Create Free Account

About Inhibikase Therapeutics Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 26, 2026
  • Source: ikt-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-126371

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API Connect Your AI